StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Ursodeoxycholsure

Ursodeoxycholic Acid

HCID 31401
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
128-13-2
Standard-SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
Summenformel
C24H40O4
Durchschnittliche Molmasse
392,6 g/mol
Monoisotopische Masse
392,29265975

Überblick

Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a mouse metabolite and a human metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of an ursodeoxycholate.

Namen und Bezeichner

Bevorzugter Name
Ursodeoxycholic Acid
IUPAC
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
Lokaler Name
Ursodeoxycholsure
Englischer Name
Ursodeoxycholic acid
Summenformel
C24H40O4
Molmasse
392.57

Namen und Synonyme

URSODEOXYCHOLIC ACIDursodiol128-13-2UDCAActigallUrsodesoxycholic acidUrso ForteDeursil3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acidAcido ursodeoxicolicoUrso 250Ursonorm
Weitere Namen anzeigen
UrsodeoxycholicURSODEOXYCHOLATETauroursodiol3-alpha,7-beta-dihydroxy-5-beta-cholanoicacidUrosodeoxycholic AcidPorcine deoxycholic acidurso
Acidum ursodeoxycholicum(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acidacide ursodeoxycholiqueDTXSID6023731724L30Y2QRDeoxyursocholic AcidNSC-683769

Datenbank-Bezeichner

CAS
128-13-2
PubChem CID
31401
DTXSID

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,9
Polarare Oberfläche (TPSA)
77,8 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
4
Schwere Atome
28
Formalladung
0
Komplexität
605

Experimentelle und physikochemische Eigenschaften

Chemical ClassesBile Acids -> Quant Bile Acids
Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LipidsLipids -> Sterol Lipids [ST] -> Bile acids and derivatives [ST04] -> C24 bile acids, alcohols, and derivatives [ST0401]
LogP3.00
Solubility0.02 mg/mL
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Bile Acids and Salts; Cholagogues and Choleretics; Cholic Acids; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 Einträge

200-205

203 °C

Physical DescriptionSolid
Collision Cross Section · 5 Einträge

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 4.5% (2 of 44) of reports.

Warning

H315 (95.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

REACH registered substance: Ursodeoxycholic acid (EC: 204-879-3)

Ursodeoxycholic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.beta.)-: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (95.5%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

n multiple clinical trials in a variety of conditions, ursodiol has not been found to cause increases in serum enzyme elevations, worsening of underlying liver disease or clinically apparent liver injury. Nevertheless, there have been rare reports of clinical decompensation in patients with advanced liver disease and cirrhosis started on ursodiol, but the reason for such reactions is not known. In at least one instance, there was recurrence of jaundice on restarting ursodiol. Thus, ursodiol has beneficial effects on several forms of liver disease and has not been convincingly linked to cases of clinically apparent acute liver injury in patients without cirrhosis. There is some concern that ursodiol may be harmful in patients with advanced liver disease (Childs class B and C) and such patients probably should not receive ursodiol.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

A05AA02

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingUnconjugated ursodeoxycholic acid is at least 70% bound to plasma proteins in health individuals. There is no information regarding the protein binding of conjugated ursodeoxycholic acid.
Pharmacodynamics · 1 Eintrag

Ursodeoxycholic acid (UDCA) is a secondary bile acid with cytoprotectant, immunomodulating, and choleretic effects. It reduces the cholesterol fraction of biliary lipids. UDCA inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation. UDCA increases bile acid flow and promotes the secretion of bile acids.

Mechanism of Action · 1 Eintrag

Endogenous hydrophobic bile acids such as deoxycholic acid and chenodeoxycholic acid can exert hepatotoxic effects. Ursodeoxycholic acid is a hydrophilic bile acid that mediates its biological effects via several mechanisms. Ursodeoxycholic acid (UDCA) protects hepatocytes and cholangiocytes from bile acid-induced damage, such as reactive oxygen species (ROS)-induced inflammation and mitochondrial dysfunction. UDCA was shown to reserve hepatocyte cell structures and stimulate anti-apoptotic pathways. It was also shown to prevent the production of ROS by Kupffer cells and resident macrophages in the liver, thus attenuating oxidative stress in the liver. UDCA can also change the hydrophobicity index of the bile acid pool: following oral administration, UDCA forms a major fraction of the human bile acid pool and competitively displaces the hydrophobic or more toxic bile acids. It increases the absorption of hydrophilic bile acids. There are several proposed mechanisms of choleretic actions of UDCA: UDCA increases intracellular calcium levels, stimulating transport proteins and vesicular exocytosis in cholestatic hepatocytes. UDCA may also upregulate the expression of membrane transport proteins like the chloride-bicarbonate anion exchanger (AE2), which is involved in biliary secretion and is often observed to be defective in primary biliary cholangitis. In rats, UDCA reduced hepatic expression of major histocompatibility complex (MHC) class I antigens, suggesting immunomodulating effects. UDCA acts as a partial agonist at the bile acid receptor, also known as the farnesoid X receptor (FXR), and has negligible effects on cholesterol and lipid synthesis.

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 464235
HRID 464235als Produkt
Reaktionsgleichung von HRID 865406
HRID 865406als Edukt
Reaktionsgleichung von HRID 893896
HRID 893896als Produkt
Reaktionsgleichung von HRID 1153703
HRID 1153703als Produkt
Reaktionsgleichung von HRID 1659375
HRID 1659375als Produkt
Reaktionsgleichung von HRID 1721147
HRID 1721147als Edukt
Reaktionsgleichung von HRID 2371860
HRID 2371860als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID6023731
ChEMBL
CHEMBL1551
ChEBI
CHEBI:9907
UNII
724L30Y2QR
EC Number
204-879-3
Nikkaji
J2.520H

200.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: Bile Acids]

208.98 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

198.7 Ų [M+Na]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

186.8 Ų [M+H-2H2O]+ [CCS Type: DT; Method: single field calibrated]

198.86 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
203 · 203-204 °C (lit.)
Siedepunkt
437.26 °C · 437.26°C (rough estimate)
Dichte
0.9985 · 0.9985 (rough estimate)
Brechungsindex
60.5 ° · 60.5 ° (C=2, EtOH)
Flammpunkt
9 ℃ · 9℃
storage temp.
2 · 2-8°C
Löslichkeit
50 mg/mL, · ethanol: 50 mg/mL, clear
Aggregatzustand
Solid. Powder.
pka
5.04 · pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
Farbe
White - almost white.
Wasserlöslichkeit
practically insoluble
Merck
14 · 14,9889
BRN
3219888 · 3219888
Kosmetik-Inhaltsstoffe Funktionen
SKIN CONDITIONING - MISCELLANEOUSSKIN PROTECTING
InChIKey
RUDATBOHQWOJDD-UZVSRGJWSA-N
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
LogP
3 · 3-3.38 at 20℃
CAS Datenbank
128 · 128-13-2(CAS DataBase Reference)
Adverse Effects · 1 Eintrag

UDCA is a mostly well-tolerated drug. In most clinical trials, diarrhea was the most frequent adverse event observed during UDCA treatment in patients with gallstone disease, with a reported incidence of 2 to 9%. The mechanism behind this side effect is unclear. However, researchers have proposed that bacterial conversion of UDCA to chenodeoxycholic acid, which serves as a potent secretory substance, could significantly contribute to this side effect. In patients with primary biliary cirrhosis, right upper quadrant abdominal pain was the most commonly reported side effect. Reports also exist of skin reactions in those with primary biliary cirrhosis. The most common dermatological manifestation was an exacerbation of pruritus, even though UDCA has demonstrated effectiveness in relieving pruritus in patients with PBC in other trials.

Toxicity Summary · 1 Eintrag

UDCA has been shown to have potentially toxic molecular properties. UDCA breaks down into toxic lithocholic acid. After being absorbed in the small intestine, UDCA undergoes hepatic conjugation. Beyond conjugation, UDCA does not experience further breakdown by the liver or intestinal mucosa. It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to liver cells and even cause liver failure in those with compromised sulfation. It also leads to segmental bile duct injury, hepatocyte failure, and death.

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ursodiol

Ambiguous-DILI-concern

0

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

F
10
wgk
2
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29181990
RTECS-Nr.
FZ2000000
risk_code
36/37/38
Toxizität
LD50 in mice (g/kg): 0.1 i.v. (Ardenne, Reitnauer); in rats, mice (mg/kg): 2000, 6000 s.c.; 1000, 1200 i.p., 310, 260 i.v. (Ward)
hazard_code
Xi
safety_code
24/25-36-26
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Eye Irrit. 2Skin Irrit. 2
Biological Half-LifeThe estimated half-life ranges from 3.5 to 5.8 days.
Metabolism/Metabolites · 1 Eintrag

Upon administration, ursodeoxycholic acid (UDCA) enters the portal vein and into the liver, where it undergoes conjugation with glycine or taurine. UDCA is also decreased into bile. Glycine or taurine conjugates are absorbed in the small intestine via passive and active mechanisms. The conjugates can also be deconjugated in the ileum by intestinal enzymes, leading to the formation of free UDCA that can be reabsorbed and re-conjugated in the liver. Nonabsorbed UDCA passes into the colon, where it undergoes 7-dehydroxylation by intestinal bacteria to lithocholic acid. Some UDCA is epimerized to [chenodeoxycholic acid] via a 7-oxo intermediate. Chenodeoxycholic acid also undergoes 7-dehydroxylation to form lithocholic acid. These metabolites are poorly soluble and excreted in the feces. A small portion of lithocholic acid is reabsorbed, conjugated in the liver with glycine or taurine, and sulfated at the 3 position. The resulting sulfated lithocholic acid conjugates are excreted in bile and then lost in feces.

FDA Pharmacological Classification · 6 Einträge

724L30Y2QR

URSODIOL

Established Pharmacologic Class [EPC] - Bile Acid

Chemical Structure [CS] - Bile Acids and Salts

Ursodiol is a Bile Acid.

URSODIOL

MeSH Pharmacological ClassificationGastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
Absorption, Distribution and Excretion · 3 Einträge

Normally, endogenous ursodeoxycholic acid constitutes a minor fraction (about 5%) of the total human bile acid pool. Following oral administration, the majority of ursodiol is absorbed by passive diffusion, and its absorption is incomplete. Once absorbed, ursodiol undergoes hepatic extraction to about 50% in the absence of liver disease. As the severity of liver disease increases, the extent of extraction decreases. During chronic administration of ursodiol, it becomes a major biliary and plasma bile acid. At a chronic dose of 13 to 15 mg/kg/day, ursodiol constitutes 30-50% of biliary and plasma bile acids.

Ursodeoxycholic acid is excreted primarily in the feces. Renal elimination is a minor elimination pathway. With treatment, urinary excretion increases but remains less than 1% except in severe cholestatic liver disease.

The volume of distribution of ursodeoxycholic acid (UDCA) has not been determined; however, it is expected to be small since UDCA is mostly distributed in the bile in the gallbladder and small intestines.

Tissue LocationsAdrenal Cortex
Cellular LocationsExtracellular

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >10000
Anwendungen · 1 Eintrag

VerwendenUrsodeoxycholic acid (UDCS) is a cell protectant used extensively to mitigate hepatic and biliary diseases. Ursodeoxycholic acid may be used to study its specific activities that range from reduction of cholesterol absorpition, cholesterol gallstone dissolution to suppression of immune response. It is also used as an anticholelithogenic. Epimer with Chenodiol with respect to the hydroxyl group at C7.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

DiethylenglykolDiacetylChenodesoxycholsureMethylcholatKaliumchromatMethanolAcetylcholic acid5β-Cholanic acidEssigsureHydrogenchloridChromtrioxidNatrium

Nachgelagerte Produkte

24-norursodeoxycholic acidEthyl UrsodeoxycholateTauroursodeoxycholic acid sodium salt
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: Ursodeoxycholic acid is a bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. It has a role as a human metabolite and a mouse metabolite. It is a bile acid, a dihydroxy-5beta-cholanic acid and a C24-steroid. It is a conjugate acid of an ursodeoxycholate.